Bio News
AbbVie’s Skyrizi recorded $5.55 billion (approximately 8.33 trillion won) in second-quarter sales, matching Humira’s quarterly record. AbbVie raised its full-year sales forecast for Skyrizi to $21.7 billion (32.6 trillion won), surpassing Humira’s annual record. The company said new prescriptions increased even after the launch of competing oral drug Icotide, attracting four times as many new patients.
BIOBOOK TEAM
biobookmedia@biobook.co.krAsahi Kasei Wins FDA Approval for New Herpes Drug Hovlpri for Immunocompromised Adults
Mirum’s Livmarli succeeds in phase 3 trial, company seeks expanded indication for rare liver disease
Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
